Clinical risk predictors in atrial fibrillation patients following successful coronary stenting: ENTRUST-AF PCI sub-analysis.

ABSTRACT:

Aims

This subgroup analysis of the ENTRUST-AF PCI trial (ClinicalTrials.gov Identifier: NCT02866175; Date of registration: August 2016) evaluated type of AF, and CHA₂DS₂-VASc score parameters as predictors for clinical outcome.

Methods

Patients were randomly assigned after percutaneous coronary intervention (PCI) to either edoxaban (60 mg/30 mg once daily [OD]; n = 751) plus a P2Y₁₂ inhibitor for 12 months or a vitamin K antagonist [VKA] (n = 755) plus a P2Y₁₂ inhibitor and aspirin (100 mg OD, for 1-12 months). The primary outcome was a composite of major/clinically relevant non-major bleeding (CRNM) within 12 months. The composite efficacy endpoint consisted of cardiovascular death, stroke, systemic embolic events, myocardial infa

SUBMITTER: Goette A 

PROVIDER: S-EPMC8166657 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature